dilazep has been researched along with Disease Models, Animal in 9 studies
Dilazep: Coronary vasodilator with some antiarrhythmic activity.
dilazep : A member of the class of diazepanes that is 1,4-diazepane substituted by 3-[(3,4,5-trimethoxybenzoyl)oxy]propyl groups at positions 1 and 4. It is a potent adenosine uptake inhibitor that exhibits antiplatelet, antianginal and vasodilator properties.
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| "r-CBF was reduced by 40% during cerebral ischemia." | 5.26 | [Effects of dilazep on cerebral blood flow under normal conditions and recirculation impairment after cerebral ischemia (author's transl)]. ( Kawada, M; Kondo, S; Sano, N, 1981) |
| "Treatment with dilazep (0." | 1.31 | Dilazep dihydrochloride prolongs the infarct size-limiting effect of ischemic preconditioning in rabbits. ( Fujiwara, H; Sasayama, S; Tanaka, M; Yamasaki, K; Yokota, R, 2000) |
| "Myocardial infarction was induced in rabbits by 30-min coronary occlusion and 72-h reperfusion." | 1.29 | Nucleoside transport inhibitors enhance the infarct size-limiting effect of ischemic preconditioning. ( Iimura, O; Itoya, M; Miura, T; Sakamoto, J; Urabe, K, 1994) |
| "The mean value of the thrombus area in the dilazep group was 60% smaller and the distribution pattern of the thrombus by size was found to be composed of smaller thrombi than those of the control group." | 1.28 | Thrombus formation on the aorta injured by angioplasty and its prevention with dilazep in atherosclerotic rabbits. ( Asanuma, A; Fujii, M; Nobuyoshi, M; Takimoto, M; Tanaka, M, 1989) |
| "r-CBF was reduced by 40% during cerebral ischemia." | 1.26 | [Effects of dilazep on cerebral blood flow under normal conditions and recirculation impairment after cerebral ischemia (author's transl)]. ( Kawada, M; Kondo, S; Sano, N, 1981) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (33.33) | 18.7374 |
| 1990's | 3 (33.33) | 18.2507 |
| 2000's | 1 (11.11) | 29.6817 |
| 2010's | 1 (11.11) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Abrams, RPM | 1 |
| Yasgar, A | 1 |
| Teramoto, T | 1 |
| Lee, MH | 1 |
| Dorjsuren, D | 1 |
| Eastman, RT | 1 |
| Malik, N | 1 |
| Zakharov, AV | 1 |
| Li, W | 1 |
| Bachani, M | 1 |
| Brimacombe, K | 1 |
| Steiner, JP | 1 |
| Hall, MD | 1 |
| Balasubramanian, A | 1 |
| Jadhav, A | 1 |
| Padmanabhan, R | 1 |
| Simeonov, A | 1 |
| Nath, A | 1 |
| Guitart, X | 1 |
| Chern, Y | 1 |
| Ferré, S | 1 |
| Kondo, S | 1 |
| Kawada, M | 1 |
| Sano, N | 1 |
| Itoya, M | 1 |
| Miura, T | 1 |
| Sakamoto, J | 1 |
| Urabe, K | 1 |
| Iimura, O | 1 |
| Nakazawa, K | 1 |
| Moriya, T | 1 |
| Kasai, S | 1 |
| Yamazaki, T | 1 |
| Komiyama, Y | 1 |
| Shigematsu, H | 1 |
| Akiba, T | 1 |
| Koga, T | 1 |
| Hoque, AN | 1 |
| Hoque, N | 1 |
| Hara, A | 1 |
| Hashizume, H | 1 |
| Ichihara, K | 1 |
| Abiko, Y | 1 |
| Yamasaki, K | 1 |
| Tanaka, M | 2 |
| Yokota, R | 1 |
| Fujiwara, H | 1 |
| Sasayama, S | 1 |
| Nobuyoshi, M | 1 |
| Fujii, M | 1 |
| Asanuma, A | 1 |
| Takimoto, M | 1 |
| Gupta, JB | 1 |
| Seth, SD | 1 |
| Singh, U | 1 |
| Vyas, DS | 1 |
9 other studies available for dilazep and Disease Models, Animal
| Article | Year |
|---|---|
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Dr | 2020 |
Targeting the equilibrative nucleoside transporter ENT1 in Huntington disease.
Topics: Age of Onset; Animals; Animals, Genetically Modified; Biomarkers; Brain; Carrier Proteins; Corpus St | 2017 |
[Effects of dilazep on cerebral blood flow under normal conditions and recirculation impairment after cerebral ischemia (author's transl)].
Topics: Animals; Azepines; Brain Chemistry; Brain Ischemia; Cerebrovascular Circulation; Cerebrovascular Dis | 1981 |
Nucleoside transport inhibitors enhance the infarct size-limiting effect of ischemic preconditioning.
Topics: Animals; Blood Pressure; Dilazep; Disease Models, Animal; Epoprostenol; Heart Rate; Injections, Intr | 1994 |
Dilazep prevents glomerulosclerosis in accelerated Masugi nephritis in the rat.
Topics: Animals; Dilazep; Disease Models, Animal; Glomerulonephritis; Glomerulosclerosis, Focal Segmental; K | 1993 |
Cardioprotective effect of K-7259, a novel dilazep derivative, against ischemia-reperfusion damage in isolated, working rat hearts.
Topics: Animals; Dilazep; Disease Models, Animal; Heart; Lipid Peroxidation; Male; Malondialdehyde; Myocardi | 1997 |
Dilazep dihydrochloride prolongs the infarct size-limiting effect of ischemic preconditioning in rabbits.
Topics: Animals; Dilazep; Disease Models, Animal; Hemodynamics; Ischemic Preconditioning, Myocardial; Male; | 2000 |
Thrombus formation on the aorta injured by angioplasty and its prevention with dilazep in atherosclerotic rabbits.
Topics: Angioplasty, Balloon; Animals; Aorta; Arteriosclerosis; Azepines; Body Weight; Cholesterol; Dilazep; | 1989 |
Effects of dilazep in evolving myocardial infarction in dogs: a biochemical study.
Topics: Adenosine Triphosphate; Animals; Azepines; Cyclic AMP; Dilazep; Disease Models, Animal; Dogs; Fatty | 1989 |